

Priment CTU Collaboration Request Form

Please complete the form in as much detail as possible. Questions can be left blank if you are not able to provide answers currently. Please submit the form to priment@ucl.ac.uk.

Study Title:		
Short Title/Acronym		
Disease Area:	Choose an it	tem.
Chief Investigator:		
Person completing this form (if not the CI)		
Position:		
Organisation:		
Email:		
Telephone:		
1. Funding plans and status		
Name of proposed funder:		
Is this a Fellowship Application?		☐ Yes
		□ No
Deadline for submission of funding		
application:		
Provide a web link to the funding call:		
Type of application:		 ☐ Outline. ☐ Full. If full, has an outline already been submitted and/or shortlisted ☐ One stage application.
Expected date of application outcome:		
Estimated grant total (if known):		
Is this a new application or a resubmission?		☐ New application.☐ Resubmission. If a resubmission, please give reasons for previous rejection:



2. Study details	
Anticipated study start date:	
Study duration (months):	
Estimated date of First Patient First Visit (FPFV):	
Duration of recruitment period (months):	
Duration of follow-up period from baseline (months):	
Anticipated number of sites:	UK: International:
How many sites have already confirmed willingness to participate:	
Sample size (if already performed or estimated):	
3. Study setting, design and type	
Study setting:	□ Primary care□ Community care□ Secondary care□ Other, specify:
Study type:	 □ Non-CTIMP. □ CTIMP. Please request a copy of the IMP information form (PRM-FRM-001) to complete. □ Medical device. If device, please give details: □ Other. If other, please give details:
Is the CTIMP/device licensed for this disease indication? (leave blank if not a CTIMP/medical devices trial)	☐ Yes. ☐ No. If no, please give details
If a medical device trial, who is developing/owns the device? (leave blank if not a medical devices trial)	☐UCL/in house ☐Commercial company. If commercial please give details of the company and what support they will provide for the trial:
If a commercial company is developing/owns the device will they want data from the trial for marketing purposes? (leave blank if not a medical devices trial)	□Yes □No
Study phase (tick all that apply):	 ☐ Observational ☐ Feasibility study ☐ Pilot study ☐ Full randomised controlled trial



	☐ Other, specify:	
Study design:	☐ Open label	
, 0	☐ Placebo Controlled	
	☐ Randomised.	
	Number of trial arms:	
	☐ Blinded	
	☐ Cross over	
	☐ Other, specify:	
If blinded:	☐ Single blinded.	
	☐ Double blinded.	
Subjects:	☐ Healthy volunteers	
(tick all that apply)	☐ Patients	
	☐ Patients with poor prognosis/terminal	
	disease	
	☐ Patients incapable of giving consent	
	personally	
	☐ Patients in emergency situations (e.g.	
	unconscious)	
	☐ Children under 5 years of age	
	☐ Children between 5 -16 years of age	
	☐ Pregnant or nursing women	
	☐ Women of child-bearing potential	
	☐ Other, specify:	
4. Please describe your project in terms o	f PICOS (Patient, Intervention, Control,	
Outcomes and Study/Statistical design):		
P - Patient:		
I - Intervention(s):		
C - Control:		
O Outcomes and follow up periods		
O - Outcomes and follow up period:		
S - Study/Statistical design (e.g. randomised	controlled trial, case control study, pilot	
S - Study/Statistical design (e.g. randomised controlled trial, case control study, pilot study):		
5. Provide a brief summary of the researc	h question and relevant background	
information (including patient or subject population/frequency of		
condition/problem). If you have conducted a feasibility or pilot study to inform a		
trial, please provide brief details		



6. State the aims and objectives of the study. Summarise the principal research questions to be answered		
4		
7. Are you planning a pilot or feasibility study?		
\square Yes. If yes, explain how this will lead to the main study:		
□ No.		
8. State the co-applicant names and roles. Please provide the names and institution		
if there are statisticians or health economists already involved.		
9. Priment statistical & health economist support		
The CTU works with Priment statisticians and \square Yes.		
health economists to support collaborations.		
Do you agree to this?		
10. Protocol status		
□ None		
☐ Outline (please attach) ☐ Full (please attach)		
☐ Consort diagram (please attach)		
11. List any other sources of support (drug supply, equipment provision etc.)		
22. 200 any care searces of support (an agree provision etc.)		
12. Proposed Sponsorship for the research:		
UCL Sponsorship request		
☐ UCL to act as UK Legal Representative (international Sponsor) (CTIMPs only)		
Other external		
Name of external sponsor: 13. Are you working with a Research Support Services (RSS) Hub??		
☐ Yes. If yes, please name the RSS Hub:		
□ No.		
14. Have you approached any other CTUs regarding this study?		
☐ Yes. If yes which ones, what was the feedback and outcome:		
□ No.		
15. Have you already approached a Priment member about this study?		
☐ Yes. If yes, give details:		
□ No.		
16. Has the proposed CI attended a GCP training course?		
☐ Yes.		
$ \square No.$		



If yes, please provide a copy of the most recent GCP certificate.			
17. Briefly describe the clinical trials experience of the Chief Investigator and the			
current trial team (including collaborators)			
Please complete the following information if you	ur proposed study is a CTIMP and/or		
device trial.			
Number of CTIMP/Device trials the proposed CI	□ 0 (No ovnoviance)		
has been the CI for previously:	0 (No experience)		
has been the error previously.	☐ <5 (Limited experience)		
Number of CTIMPs/Daviss trials the mass and Cl	□ ≥5 (Experienced)		
Number of CTIMPs/Device trials the proposed CI	☐ 0 (No experience)		
has been a named Principal Investigator for:	☐ <5 (Limited experience)		
	☐ ≥5 (Experienced)		
Where any of these trials multi-centre:	☐ Yes.		
	\square No.		
	If yes, please give the number of		
	centres of the largest trial:		
Has the CI been involved in a clinical trial of the	☐ Yes.		
same phase as the proposed one:	□ No.		
1. Cl's Experience of IMPs/Device proposed in			
administration and familiarity with IMP/Device safe	ety profile); add additional rows for each		
IMP/device			
1. [Add Name of IMP/Device]	☐ No experience		
	\square prescribed to <50 patients (limited		
	experience)		
	☐ prescribed to ≥50 patients		
	(experienced)		
Any additional information/comments regarding			
experience or risk related to IMP, if required:			
2. Cl's Experience of Trial Procedures (Complete	•		
RISK/NOVEL procedures e.g. surgical, non-CE marke	ed device, unlicensed NIMPs); add		
additional rows for each trial procedure			
a. Does the CI have experience or experienced	☐ No experience		
staff to carry out [insert invasive study	☐ <2 years experience		
assessment (e.g. MRI scan, X-ray etc.) - delete	☐ ≥2 years experience		
if not applicable] Any additional information (comments regarding			
Any additional information/comments regarding experience or risk related to trial interventions, if			
i capelicite di lisk iciated to tilal littel (ciitibils, il			



For internal Priment use only	
Priment reference:	
Date of Steering Group meeting:	
Meeting attended by:	
Outcome of meeting:	☐ Accept☐ Request more information☐ Request presentation☐ Decline
Timelines:	
Comments/further details:	
Form completed by:	
Date completed:	